NEW YORK--(BUSINESS WIRE)--The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Amicus Therapeutics, Inc. (“Amicus Therapeutics”) (NASDAQ:FOLD) between March 19, 2015 and October 1, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. If you purchased or otherwise acquired Amicus Therapeutics between March 19, 2015 and October 1, 2015, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that the Company made false and/or misleading statements and/or failed to disclose that the United States Food and Drug Administration raised concerns about Amicus Therapeutics’ forthcoming new drug application for migalastat during their September 15, 2015 meeting.
On October 2, 2015, Amicus Therapeutics revealed it would no longer be in a position to submit its NDA in the fourth quarter of 2015. Upon this news, shares of Amicus Therapeutics fell 54% to close at $6.39 per share.
If you suffered a loss in Amicus Therapeutics you have until December 7, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.